Berberine in Cardiovascular and Metabolic Diseases: From
Mechanisms to Therapeutics

J 2019

Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics

FENG, XJ, A SUREDA, S JAFARI, Z MEMARIANI, D TEWARI et. al.

Basic information

Original name

Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics

Authors

Edition

Theranostics, Lake Haven, Ivyspring International Publisher, 2019, 1838-7640

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 8.579

Organization unit

Faculty of Pharmacy

DOI

http://dx.doi.org/10.7150/thno.30787

UT WoS

000461767700008

Keywords in English

berberine; cardiovascular diseases; metabolic diseases; targets; therapeutics

Změněno: 25/1/2021 21:02, Mgr. Michal Petr

Abstract

V originále

Cardiovascular and metabolic diseases (CVMD) are the leading causes of death worldwide, underscoring the urgent necessity to develop new pharmacotherapies. Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years. Recently, BBR has attracted much interest for its pharmacological actions in treating and/or managing CVMD. Recent discoveries of basic, translational and clinical studies have identified many novel molecular targets of BBR (such as AMPK, SIRT1, LDLR, PCSK9, and PTP1B) and provided novel evidences supporting the promising therapeutic potential of BBR to combat CVMD. Thus, this review provides a timely overview of the pharmacological properties and therapeutic application of BBR in CVMD, and underlines recent pharmacological advances which validate BBR as a promising lead drug against CVMD.

Citovat

FENG, XJ, A SUREDA, S JAFARI, Z MEMARIANI, D TEWARI, G ANNUNZIATA, L BARREA, STS HASSAN, Karel ŠMEJKAL, Milan MALANÍK, Alice SYCHROVÁ, D BARRECA, L ZIBERNA, MF MAHOMOODALLY, G ZENGIN, SW XU, SM NABAVI and AZ SHEN. Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics. Theranostics. Lake Haven: Ivyspring International Publisher, 2019, vol. 9, No 7, p. 1923-1951. ISSN 1838-7640. Available from: https://dx.doi.org/10.7150/thno.30787.

@article{1726932,
   author = {Feng, XJ and Sureda, A and Jafari, S and Memariani, Z and Tewari, D and Annunziata, G and Barrea, L and Hassan, STS and Šmejkal, Karel and Malaník, Milan and Sychrová, Alice and Barreca, D and Ziberna, L and Mahomoodally, MF and Zengin, G and Xu, SW and Nabavi, SM and Shen, AZ},
   article_location = {Lake Haven},
   article_number = {7},
   doi = {http://dx.doi.org/10.7150/thno.30787},
   keywords = {berberine; cardiovascular diseases; metabolic diseases; targets; therapeutics},
   language = {eng},
   issn = {1838-7640},
   journal = {Theranostics},
   title = {Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics},
   volume = {9},
   year = {2019}
}

TY  - JOUR
ID  - 1726932
AU  - Feng, XJ - Sureda, A - Jafari, S - Memariani, Z - Tewari, D - Annunziata, G - Barrea, L - Hassan, STS - Šmejkal, Karel - Malaník, Milan - Sychrová, Alice - Barreca, D - Ziberna, L - Mahomoodally, MF - Zengin, G - Xu, SW - Nabavi, SM - Shen, AZ
PY  - 2019
TI  - Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics
JF  - Theranostics
VL  - 9
IS  - 7
SP  - 1923-1951
EP  - 1923-1951
PB  - Ivyspring International Publisher
SN  - 18387640
KW  - berberine
KW  - cardiovascular diseases
KW  - metabolic diseases
KW  - targets
KW  - therapeutics
N2  - Cardiovascular and metabolic diseases (CVMD) are the leading causes of death worldwide, underscoring the urgent necessity to develop new pharmacotherapies. Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years. Recently, BBR has attracted much interest for its pharmacological actions in treating and/or managing CVMD. Recent discoveries of basic, translational and clinical studies have identified many novel molecular targets of BBR (such as AMPK, SIRT1, LDLR, PCSK9, and PTP1B) and provided novel evidences supporting the promising therapeutic potential of BBR to combat CVMD. Thus, this review provides a timely overview of the pharmacological properties and therapeutic application of BBR in CVMD, and underlines recent pharmacological advances which validate BBR as a promising lead drug against CVMD.
ER  -

FENG, XJ, A SUREDA, S JAFARI, Z MEMARIANI, D TEWARI, G ANNUNZIATA, L BARREA, STS HASSAN, Karel ŠMEJKAL, Milan MALANÍK, Alice SYCHROVÁ, D BARRECA, L ZIBERNA, MF MAHOMOODALLY, G ZENGIN, SW XU, SM NABAVI and AZ SHEN. Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics. \textit{Theranostics}. Lake Haven: Ivyspring International Publisher, 2019, vol.~9, No~7, p.~1923-1951. ISSN~1838-7640. Available from: https://dx.doi.org/10.7150/thno.30787.

Detailed Information on Publication Record